RBX2660 has been granted Orphan Drug status, Fast Track status and gained Breakthrough Therapy Designation from the FDA in October 2015 for its potential to prevent recurrent C. diff. infection.

Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...

While CDI can be resolved with antibiotics, the drugs are often ineffective against dormant spore forms of C. diff, which can germinate and grow after the course is completed. CDI causes nearly ...

The portion of our nervous systems responsible for the "fight or flight" response can shape the severity of potentially ...

Pharmaceuticals announced updates on Phase 3 Readiness for Ibezapolstat in C. difficile Infection based on recent FDA and EMA ...

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a late-stage biopharmaceutical company developing a new class of small molecule antibiotics for difficult-to-treat bacterial ...

Acurx Pharmaceuticals (NASDAQ:ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. The biotech company said the ...